2 Deoxythioguanosine - MAIA Biotechnology
Alternative Names: 2'-Deoxythioguanosine; 6-thio-2’-deoxyguanosine - MAIA Biotechnology; 6-thio-dG - MAIA Biotechnology; THIO - MAIA BiotechnologyLatest Information Update: 15 Sep 2024
At a glance
- Originator MAIA Biotechnology
- Class Amines; Antineoplastics; Deoxyribonucleosides; Purines; Small molecules; Thiones
- Mechanism of Action Cell death stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Cancer
Highest Development Phases
- Phase II Non-small cell lung cancer
- Preclinical Glioma; Liver cancer; Small cell lung cancer
Most Recent Events
- 10 Sep 2024 Updated efficacy data from the phase II THIO-101 trial in Non-small cell lung cancer released by MAIA Biotechnology
- 04 Jun 2024 Updated efficacy data from a phase II THIO-101 trial in Non-small cell lung cancer released by MAIA Biotechnology
- 31 May 2024 Efficacy and adverse events data from a phase II trial in Non small cell lung cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)